Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis
• Interim Results Demonstrate Strong Clinical Improvement and Favorable Safety Profile
• Final Data Expected in Fourth Quarter of 2016
Viamet Pharmaceuticals, Inc. today reported positive results from a planned interim analysis of RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation), its ongoing Phase 2b clinical trial of VT-1161 in onychomycosis of the large toenail. VT-1161, the company’s lead product candidate, is a highly potent and selective, orally available inhibitor of fungal CYP51.